316
Views
5
CrossRef citations to date
0
Altmetric
Letter

Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide

, , , &
Pages 1003-1005 | Received 20 Aug 2011, Accepted 30 Oct 2011, Published online: 06 Dec 2011

References

  • Hinchey J, Chaves C, Appignani B, . A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.
  • Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol 2007;28:1320–1327.
  • Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008;10:86–91.
  • Ay H, Buonanno FS, Schaefer PW, . Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369–1376.
  • Bartynski WS. Posterior reversible encephalopathy syndrome, Part 2: Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008;29:1043–1049.
  • Connolly RM, Doherty CP, Beedy P, . Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 2007;56:459–463.
  • Bartynski WS, Boardman JF, Zeigler ZR, . Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. Am J Neuroradiol 2006;27:2179–2190.
  • Bartynski WS, Upadhyaya AR, Boardman JF. Posterior reversible encephalopathy syndrome and cerebral vasculopathy associated with influenza A infection: report of a case and review of the literature. J Comput Assist Tomogr 2009;33:917–922.
  • Tam CS, Galanos J, Seymour JF, . Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic maligancies. Am J Hematol 2004;77:72–76.
  • Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475–1478.
  • Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980–981.
  • Mitsiades N, Mitsiades CS, Poulaki V, . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
  • Yabu T, Tomimoto H, Taguchi Y, . Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005;106:125–134.
  • Pandey R, Patel A, Shah S, . A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone—reversible posterior lobe leukoencephalopathy. Leuk Lymphoma 2006;47:1431–1434.
  • Lebrun C, Chanalet S, Frenay M, . Leukoencephalopathy in multiple myeloma: two case reports. Ann Oncol 1999;10:1515–1517.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.